|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-5-21
|
|
pubmed:abstractText |
Torcetrapib, a prototype cholesteryl ester transfer protein (CETP) inhibitor with potential for decreasing atherosclerotic disease, increased cardiovascular events in clinical trials. The identified hypertensive and aldosterone-elevating actions of torcetrapib may not fully account for this elevated cardiovascular risk. Therefore, we evaluated the effects of torcetrapib on endothelial mediated vasodilation in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1533-4023
|
|
pubmed:author |
pubmed-author:ChenCailinC,
pubmed-author:CheungWai-ManWM,
pubmed-author:ConnellyMargery AMA,
pubmed-author:CoolsFrankF,
pubmed-author:DamianoBruce PBP,
pubmed-author:DemarestKeith TKT,
pubmed-author:GallacherDavid JDJ,
pubmed-author:GiardinoEdward CEC,
pubmed-author:HuangZhihongZ,
pubmed-author:KuoGee-HongGH,
pubmed-author:ParryTom JTJ,
pubmed-author:SarichTroy CTC,
pubmed-author:Van der LindeHenkH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
459-68
|
|
pubmed:meshHeading |
pubmed-meshheading:20051879-Administration, Oral,
pubmed-meshheading:20051879-Animals,
pubmed-meshheading:20051879-Anticholesteremic Agents,
pubmed-meshheading:20051879-Cardiovascular Diseases,
pubmed-meshheading:20051879-Cholesterol Ester Transfer Proteins,
pubmed-meshheading:20051879-Dose-Response Relationship, Drug,
pubmed-meshheading:20051879-Endothelium, Vascular,
pubmed-meshheading:20051879-Injections, Intravenous,
pubmed-meshheading:20051879-Male,
pubmed-meshheading:20051879-Molecular Structure,
pubmed-meshheading:20051879-Quinolines,
pubmed-meshheading:20051879-Rabbits,
pubmed-meshheading:20051879-Vasodilation
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
|
|
pubmed:affiliation |
Johnson & Johnson Pharmaceutical Research and Development, Welsh & McKean Roads, Spring House, PA 19477-0776, USA. mconnell@its.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
